ResMed (FRA:RMEA) Tax Provision: €-341 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RMEA ResMed Inc FRA:RMEA
90 GF Score
Price €17.10
GF Value €23.14
! 1 Warning Sign
View Full Analysis

What is ResMed Tax Provision?

ResMed FRA:RMEA -9.04% 90 Tax Provision is €-341 Mil as of Jun. 2026. GuruFocus rates FRA:RMEA with a GF Score™ of 90/100 and a GF Value™ of €23.14. The stock has 1 warning sign investors should review.

ResMed's tax provision for the three months ended in Jun. 2026 was €-79 Mil. Its tax provision for the trailing twelve months (TTM) ended in Jun. 2026 was €-341 Mil.

ResMed Tax Provision Historical Data

* Premium members only.

The historical data trend for ResMed's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed Tax Provision Chart

ResMed Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -171.27 -188.39 -226.53 -240.02 -343.84

ResMed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -67.93 -83.72 -88.44 -89.60 -78.76
FRA:RMEA
90GF Score
ResMed Inc FRA:RMEA
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-341 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of €-341 Mil mean?
ResMed (FRA:RMEA) has a Tax Provision of €-341 Mil as of Jun. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on ResMed and its competitors.
Is ResMed's Tax Provision too high?
ResMed's current Tax Provision is €-341 Mil. Overall, ResMed has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does ResMed's Tax Provision compare to MDLN and WST?
ResMed's Tax Provision of €-341 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Medical Devices & Instruments company?
A good Tax Provision depends on the Medical Devices & Instruments industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on ResMed and its competitors. ResMed's current Tax Provision is €-341 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
ResMed (FRA:RMEA) has a current Tax Provision of €-341 Mil. The stock's GF Value™ is €23.14, compared to a current price of €17.10 — trading 26.1% below its estimated fair value. The current Tax Provision is €-341 Mil. ResMed's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For ResMed (FRA:RMEA), the current Tax Provision is €-341 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ResMed (FRA:RMEA) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of €17.10 is trading 26.1% below its estimated GF Value™ of €23.14.

Key valuation signals for FRA:RMEA:

  • Tax Provision: €-341 Mil
  • GF Value™: €23.14 vs. price of €17.10 (26.1% below fair value)
  • GF Score™: 90/100 with 1 warning sign

No single metric tells the full story. See the FRA:RMEA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
90GF Score

Get the complete analysis for FRA:RMEA

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.10
Price
€23.14
GF Value